에 대한 최신 뉴스 Canaan (NASDAQ:CAN) 주식

CANAAN INC

Canaan

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.

bitcoin-7678816_1280

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

News

Previews

Global

Movers

$BTC

BITF

HIVE

비트코인(CRYPTO: BTC)이 도널드 트럼프의 당선 이후 사상 최고가로 급등했으며, 이는 긍정적인 시장 심리의 파도로 비트코인 채굴 관련 주식들도 상승하는 결과를 가져왔다.

비트코인이 최고가를 경신하는 가운데 채굴업체 하이브 디지털, 헛 8 및 비트팜즈 실적 발표

Canaan Inc

Can B Corp

Tema Oncology ETF

Teucrium Sugar Fund ETV

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd

Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares

Cango Inc

CannLabs Inc

Trees Corp

CALIFORNIA NANOTECHS CORP by California Nanotechnologies Corp

California Nanotechnologies Corp

Cano Health Inc Ordinary Shares - Class A

Cano Health Inc Warrants (03/06/2026)

Cian PLC

Calamos Alternative Nasdaq & Bond ETF

CANAQUEST MED CORP by CanaQuest Medical Corporation

CanaQuest Medical Corp

CANARE ELECTRIC CO LTD by CANARE ELECTRIC CO LTD

Canare Electric Co Ltd

WILLOW BIOSCIENCES INC by Willow Biosciences Inc.

Willow Biosciences Inc

CAVENDISH HYDROGEN ASA by CAVENDISH HYDROGEN ASA

Market analysts say President Donald Trump's newly announced global tariff regime is already reshaping investor sentiment, triggering sharp corrections <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44625640/anthony-pompliano-praises-trumps-tariffs-as-catalyst-for-crypto-innovation">across risk assets—including crypto. </a>
While digital currencies initially showed some resilience, experts caution that they remain exposed to broader macroeconomic shocks.
Trump's April 2 speech, which introduced a "reciprocal tariff" program with baseline rates starting at 10% and scaling up to 50% by April 9, caused immediate <a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">volatility in financial markets</a>.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has dipped below $82,000, while U.S. equity futures and global ETFs slid.
Trump described the move as a "Declaration of Economic Independence," aimed at rebalancing global trade dynamics.
According to David Hernandez, a crypto investment specialist at 21Shares, the tariffs removed some ambiguity around U.S. trade policy but raised new concerns. 
"Markets thrive on clarity, and now that the scope is known, we may see institutions buy the dip," he said. "Still, the announcement rattled equities and crypto alike. Bitcoin held above key support at $82,000 but couldn't avoid broader risk-off pressure."
James Toledano, COO at Unity Wallet, observed that crypto wasn't immune to the impact. 
"Bitcoin is down 4.9% on the week, holding around $82,000," he said. "This shows that in the early stages of global instability, digital assets behave more like tech stocks than safe havens."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44628685/bitcoin-is-a-realistic-global-reserve-asset-experts-say">Bitcoin Is A Realistic Global Reserve Asset, Experts Say</a>
Toledano added that if the situation escalates into a prolonged economic standoff, crypto could gain renewed appeal. "We're not at safe haven status yet, but if confidence in fiat wavers, Bitcoin might decouple over time."
Javier Rodriguez-Alarcon, Chief Commercial Officer at XBTO, echoed that view, noting the correlation between Bitcoin and traditional markets during moments of high volatility. "Bitcoin still trades like a risk asset during policy shocks. That doesn't negate its long-term potential, but the narrative as a hedge is still maturing."
He added that as digital assets gain wider institutional traction, future dislocations may see crypto react differently. 
For now, however, "the sell-off shows crypto is still subject to the same sentiment-driven dynamics that move traditional finance."
Despite these headwinds, Hernandez noted that institutional inflows into Bitcoin ETFs remained steady, suggesting some investors may view the dip as an entry point. 
"The market reaction underscores Bitcoin's borderless appeal in hedging against geopolitical uncertainty," he said.
With key U.S. trading partners expected to respond in the coming days, including China, South Korea, and Mexico, analysts say further volatility is likely across all asset classes—crypto included.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44627407/gold-overtaking-bitcoin-in-inflation-hedge-strategy-jpmorgan-says">Gold Overtaking Bitcoin In Inflation Hedge Strategy, JPMorgan Says</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Bitcoin As Trump Tariff Safe Haven? Not Yet, But 'Might Decouple Over Time,' Expert Says

Dutch advanced chipmaking equipment supplier ASML Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) plans to quintuple its Japan-based maintenance staff for the machines in the next few years, Nikkei <a target="_blank" href="https://asia.nikkei.com/Business/Tech/Semiconductors/ASML-to-quintuple-advanced-EUV-chip-tools-staff-in-Japan" rel="noreferrer noopener">reported</a> Tuesday.
ASML manufactures extreme ultraviolet (EUV) lithography equipment for making advanced technology chips.
In December, Rapidus became the first Japanese chipmaker to receive EUV machines.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43945751/huawei-boosts-ai-chip-production-despite-taiwan-semi-and-asml-ban-aims-to-challenge-nvidia-in-china" rel="noreferrer noopener">Huawei Boosts AI Chip Production Despite Taiwan Semi And ASML Ban, Aims to Challenge Nvidia In China</a>
Japan continues bolstering its advanced semiconductor technology position, as in the U.S., Europe, and China.
Japanese multinational investment holding company Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) is <a target="_blank" href="https://www.benzinga.com/media/25/04/44589685/softbank-weighs-165-billion-loan-that-could-back-openais-40-billion-raise-report" rel="noreferrer noopener">weighing a loan</a> of up to $16.5 billion to finance its&nbsp;U.S. artificial intelligence ambitions. The loan may help SoftBank lead a $40 billion&nbsp;funding round&nbsp;in OpenAI. The move values the ChatGPT parent&nbsp;at $300 billion.
Contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expanding globally with <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42843001/taiwan-semiconductor-ramps-up-production-in-japan-us-and-germany-to-diversify-away-from-china" rel="noreferrer noopener">plants in the U.S., Japan, and Germany</a>.
Meanwhile, ASML continues to gain traction, which is backed by the higher demand for semiconductor chips.
In March, ASML and imec forged a <a target="_blank" href="https://www.benzinga.com/markets/eurozone/25/03/44253751/asml-boosts-ai-chip-rd-in-europe-amid-us-sanctions-china-slowdown-and-subsidy-uncertainty" rel="noreferrer noopener">five-year deal</a> complemented by funding made available by the Chips Joint Undertaking, the Flemish government, and&nbsp;the Dutch government to boost semiconductor R&amp;D and sustainable innovation with EU and government backing to develop sub-2nm chips and advance AI-ready semiconductor solutions.
ASML Holding stock has plunged 34% in the last 12 months. The company disclosed in its&nbsp;annual report that the U.S. semiconductor sanctions on China hurt 2024 demand, with China making up 36% of its sales.
ASML customers slashed capital spending amid U.S. chip restrictions, impacting AI and semiconductor growth. Additionally, reports indicated President Donald Trump&#8217;s plans to scrap&nbsp;the U.S. CHIPS Act.
The EUV lithography market size was worth $10.09 billion in 2023 and is <a target="_blank" href="https://www.globenewswire.com/news-release/2025/03/21/3047088/0/en/Extreme-Ultraviolet-EUV-Lithography-Market-to-Hit-USD-35-70-billion-by-2032-Driven-by-Rising-Demand-for-Advanced-Semiconductor-Manufacturing-SNS-Insider.html" rel="noreferrer noopener">expected to reach</a> $35.70 Billion by 2032 and grow at a CAGR of 15.1% over the forecast period 2024-2032.
The growth potential reflects technological advancements, increasing semiconductor complexity, and the demand for smaller, more powerful chips. Industries like AI, high-performance computing, 5G, and IoT.
Price Action:&nbsp;ASML stock is down 4.55% at $638.55 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43938789/intel-deploys-asmls-advanced-euv-machines-aims-to-challenge-taiwan-semiconductors-lead" target="_blank" rel="noreferrer noopener">Intel Deploys ASML&#8217;s Advanced EUV Machines, Aims to Challenge Taiwan Semiconductor&#8217;s Lead</a></li>
</ul>
Photo via Shutterstock

Asia

Tech

Media

ASML

SFTBF

SFTBY

Chip Equipment Maker ASML To Boost Japan Workforce 5x Amid Global Race For Advanced Semiconductor Tech

Trading Ideas

OTIS

Live On CNBC: Josh Brown Buys OTIS

KinderCare Learning Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) is under fire Thursday following a <a href="https://thebearcave.substack.com/p/problems-at-kindercare-learning-companies">new report</a> from The Bear Cave, which alleges safety failures, regulatory concerns and a deteriorating reputation at the nation's <a href="https://www.benzinga.com/quote/KLC">largest private childcare provider</a>.
What Happened: The Bear Cave released a short report on KinderCare Thursday, alleging the company is plagued by operational failures that could threaten its stock performance.
"Recent investigations reveal alarming safety incidents, including children left unsupervised, instances of abuse and regulatory violations that raise serious concerns about KinderCare's ability to operate responsibly," the short seller said.
Benzinga has reached out to KinderCare Learnings Companies for comment on the report.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44629335/apple-stock-slammed-by-trump-tariffs-is-a-death-cross-next">Apple Stock Slammed By Trump Tariffs: Is A Death Cross Next?</a>
KinderCare operates roughly 1,500 childcare centers across 41 states and relies heavily on government funding. The company went public in 2022, positioning itself as a leader in early childhood education.
The Bear Cave&#8217;s report cites troubling incidents, including a <a href="https://www.jsonline.com/story/communities/south/2024/11/20/cudahy-woman-pleads-guilty-in-oak-creek-kindercare-cocaine-case/76434101007/">case</a> where an 11-month-old tested positive for cocaine at a KinderCare center in Wisconsin. Other reports detail children <a href="https://wcti12.com/news/local/teachers-on-leave-after-toddler-wanders-onto-busy-road-from-daycare">escaping</a> facilities, being <a href="https://www.nbcnews.com/news/us-news/florida-mom-finds-toddler-locked-day-care-workers-left-day-rcna16918">locked</a> inside after closing hours and experiencing mistreatment by staff.
&#8220;In sum, The Bear Cave believes KinderCare is a broken business that harms the children and families it claims to help,&#8221; the short seller said.
The Bear Cave reported that KinderCare has faced repeated scrutiny from regulatory agencies. The short seller believes growing concerns could impact its ability to secure funding and expand operations.
The short seller also highlighted online complaints from parents and former employees, with some alleging understaffing, inadequate training and neglect.
KLC Price Action: <a href="http://benzinga.com/quote/klc">KinderCare shares</a> are falling by 10.8 % during Thursday&#8217;s session, trading at $11.40 at the time of publication. According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, KinderCare has a 52-week high of $29.89 and a 52-week low of $10.91 after making new lows for the year in Thursday&#8217;s session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44628368/trumps-tariffs-prompt-china-to-vow-countermeasures-experts-see-retaliation-likely" target="_blank" rel="noreferrer noopener">Trump's Tariffs Prompt China To Vow ‘Countermeasures': Experts See Retaliation Likely</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/lordn">Lordn</a>/Shutterstock.

Short Sellers

Short Ideas

Short Seller Slams KinderCare Over Safety Failures, Stock Hits New 52-Week Low

WIIM

ACDC

CGBS

CIVI

EQNR

FANG

SHEL

Shares of energy companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Truist Securities analyst William Stein maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold and lowers the price target from $373 to $280.

Price Target

Analyst Ratings

TSLA

Truist Securities Maintains Hold on Tesla, Lowers Price Target to $280

TIVC

Tivic Health Shares resume Trading

Tivic Health Shares Halted On Circuit Breaker To Downside; Stock Up 53.9%

Genius Group Ltd (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares are trading lower on Thursday following news that the company is being compelled <a href="https://www.benzinga.com/pressreleases/25/04/g44625455/genius-group-blocked-from-raising-funds-and-buying-bitcoin-by-new-york-court" target="_blank" rel="noreferrer noopener">to sell its Bitcoin treasury.</a>
The move comes after a court ruling in the U.S. District Court Southern District of New York, which blocked Genius from selling shares, raising funds and using investor money to purchase Bitcoin.
This injunction was granted as part of a larger legal battle with Fatbrain AI, part of Lzg International Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZGI#OTC">LZGI</a>), where Genius had initiated arbitration to terminate its asset purchase agreement with the company.
The court&#8217;s decision is based on fraud allegations against LZGI executives Michael Moe and Peter Ritz, who have been accused of defrauding shareholders.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/25/04/44627817/retaliation-odds-spike-after-trumps-heavy-tariffs-sending-country-etfs-tumbling" rel="noreferrer noopener">Retaliation Odds Spike After Trump&#8217;s Heavy Tariffs, Sending Country ETFs Tumbling</a>
Genius filed motions and presented evidence of what it claims is a scheme to extort money from the company through the legal process.
As a result, Genius&#8217;s ability to finance its operations and issue share compensation to employees has been blocked, forcing the company to consider drastic measures.
In response, Genius is actively appealing the injunction, while restructuring its operations, including downsizing and halting marketing and investment activities.
The company has been forced to sell some of its Bitcoin holdings to sustain operations, reducing its treasury from 440 Bitcoin to 430 Bitcoin.
Despite the challenges, CEO Roger James Hamilton remains committed to fighting fraud and market manipulation and intends to protect shareholders&#8217; interests.
The ongoing restrictions, however, pose a serious risk to the company's future operations, with Genius&#8217; stock price falling 53% since the temporary restraining order was imposed.
GNS Price Action: Genius shares are trading lower by 11.88% to 22 cents at publication Thursday.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/25/04/44624245/tariffs-to-plug-the-hole-for-income-tax-cuts-to-come-economists-predict-what-more-could-be-expected" target="_blank" rel="noreferrer noopener">Trump Tariffs To ‘Plug The Hole' For Income Tax Cuts To Come: Economists Predict What More Could Be Expected</a></li>
</ul>
Photo: Courtesy Genius Group

Legal

Markets

General

LZGI

What's Going On With Genius Group Stock Today?

CART

CASY

CELH

CHEF

COST

HNST

PFGC

USFD

Shares of companies within the broader consumer staples sector are trading lower as markets react to President Trump's announcement of sweeping tariffs.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 800 points on Thursday.
The Dow traded down 3.07% to 40,929.87 while the NASDAQ fell 4.83% to 16,750.33. The S&amp;P 500 also fell, dropping, 3.73% to 5,459.39.
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44625270/top-3-tech-and-telecom-stocks-youll-regret-missing-this-month">Top 3 Tech And Telecom Stocks You&#8217;ll Regret Missing This Month</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.4% on Thursday.
In trading on Thursday, energy shares tumbled by 5.6%.
Top Headline
The ISM services PMI dipped to 50.8 in March versus a reading of 53.5 in February, and down from market estimates of 53.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares shot up 10% to $59.60 after the company reported better-than-expected third-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Shares of NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>)got a boost, surging 95% to $1.15 after the company announced it secured $5.2 million in funding to drive international expansion.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) shares were also up, gaining 12% to $10.19.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Aldeyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares dropped 76% to $1.2750 after the company received a response letter from the FDA for the Reproxalap new drug application for the treatment of signs and symptoms of dry eye disease.</li>
<li>Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) were down 41% to $147.59 after the company reported weaker-than-expected fourth-quarter financial results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) was down, falling 22% to $26.30. Shares of specialty retailers in the furniture and home goods space traded lower following disappointing earnings from RH.</li>
</ul>
Commodities In commodity news, oil traded down 7.1% to $66.64 while gold traded down 1.8% at $3,110.80.
Silver traded down 7.1% to $32.205 on Thursday, while copper fell 3.4% to $4.8705.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 2.19%, Germany's DAX 40 dipped 2.11% and France's CAC 40 fell 2.93%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.30%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 dipping 2.77%, China's Shanghai Composite Index falling 0.24%, Hong Kong's Hang Seng Index falling 1.52% and India's BSE Sensex falling 0.42%.
Economics
<ul>
<li>U.S. initial jobless claims fell by 6,000 to 219,000 in the week ending March 29, compared to market estimates of 225,000.</li>
<li>The U.S. trade deficit shrank to $122.7 billion in February compared to $130.7 billion in the previous month and versus market estimates of a $123.5 billion gap.</li>
<li>The S&amp;P Global services PMI was revised higher to 54.4 in March compared to a preliminary reading of 54.3.</li>
<li>The S&amp;P Global composite PMI climbed to 53.5 in March versus 51.6 in the previous month.</li>
<li>The ISM services PMI dipped to 50.8 in March versus a reading of 53.5 in February, and down from market estimates of 53.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

ALDX

NIVF

Crude Oil Dips 7%; ISM Services PMI Falls In March

Macro Economic Events

Econ #s

Economics

Canada PM Carney Says: He May Speak With Trump Again But Nothing Scheduled

PAAS

Shares of precious metals stocks are trading lower as markets react to President Trump's announcement of sweeping tariffs.

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">rapid disease progression</a>.
Vanrafia is a once-daily, non-steroidal, oral treatment that can be added to supportive care, including a renin-angiotensin system inhibitor with or without a sodium-glucose co-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44619827/novartis-receives-fda-accelerated-approval-for-vanrafia-atrasentan-the-first-and-only-selective-en" rel="noreferrer noopener">transporter-2 inhibitor</a>.
Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase 3 ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44592342/apellis-pharmaceuticals-rare-kidney-disease-drug-under-fda-review-seeks-to-compete-novartis-recently-approved-drug" rel="noreferrer noopener">FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals</a>
It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.
The continued approval of Vanrafia may be contingent upon verifying clinical benefit from the ongoing Phase 3 ALIGN study evaluating whether Vanrafia slows disease progression as measured by estimated glomerular filtration rate (eGFR) decline at week 136.
The eGFR data are expected in 2026 and are intended to support traditional FDA approval.
In the ongoing Phase 3 ALIGN study, patients receiving Vanrafia in combination with a RAS inhibitor achieved clinically meaningful and statistically significant proteinuria reduction of 36.1% compared to placebo, with results seen as early as week 6 and sustained through week 36.
A similar treatment effect of Vanrafia was seen in an additional group of patients treated with both an RAS inhibitor and an SGLT2 inhibitor (37.4% reduction in UPCR vs. placebo).
The ALIGN study showed that Vanrafia has a favorable safety profile consistent with previously reported data.
This is Novartis&#8217;s third U.S. approval for its kidney disease portfolio in the last year. Fabhalta&nbsp;was granted FDA approval in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">C3 glomerulopathy in&nbsp;March 2025</a> and accelerated approval in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40254535/fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease" rel="noreferrer noopener">IgAN in&nbsp;August 2024</a>.
Fabhalta is also being studied in rare kidney diseases, including atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis, and lupus nephritis.
An investigational subcutaneously administered anti-APRIL monoclonal antibody, zigakibart, is currently in Phase 3 development in IgAN, with results expected in 2026.
Price Action: NVS stock is up 2.16% at $113.17 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44614171/uks-health-agency-endorses-pfizers-blood-cancer-combo-therapy-as-first-for-untreated-hodgkin-lymphoma-patients" target="_blank" rel="noreferrer noopener">UK&#8217;s Health Agency Endorses Pfizer&#8217;s Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Health Care

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

The <a href="https://www.benzinga.com/topic/u-s-food-and-drug-administration">U.S. Food and Drug Administration</a> (FDA) on Thursday granted orphan drug designation to Sanofi SA&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) rilzabrutinib.
The treatment is an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">IgG4-related disease (IgG4-RD)</a>.
The FDA grants orphan drug designation to investigational therapies that address rare medical diseases or conditions that affect fewer than 200,000 people in the US.
Rilzabrutinib is <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-03-05-00-00-3054815" rel="noreferrer noopener">currently</a> under regulatory review in the US, the EU, and China for its potential use in immune thrombocytopenia (ITP).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" rel="noreferrer noopener">Pharmaceutical Firms Say UK Investment Is &#8216;Unlikely&#8217; Unless Payment Levy Is Addressed</a>
The target action date for the FDA regulatory decision on ITP, which was granted fast-track designation, is Aug. 29.
Rilzabrutinib also received orphan drug designation for ITP in the US, EU, and Japan.
Results from a phase 2b study on wAIHA&nbsp;presented at ASH 2024 demonstrated that treatment with rilzabrutinib showed clinically meaningful outcomes on response rate and disease markers.
In IgG4-RD patients, results from a phase 2a study showed treatment with rilzabrutinib for 52 weeks led to reduction in disease flare, other disease markers, and glucocorticoid sparing.
The safety profile of rilzabrutinib in both studies was consistent with previous studies.
Last week, the FDA approved&nbsp;Sanofi&#8217;s Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with hemophilia A or B with or without&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44560065/fda-approves-sanofis-hemophilia-drug" rel="noreferrer noopener">factor VIII or IX inhibitors</a>.
The&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-28-20-07-38-3051637" rel="noreferrer noopener">approval</a>&nbsp;is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates.
Price Action: Sanofi&#8217;s stock is up 3.54% at $55.86 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613863/biomarin-seeks-label-expansion-for-palynziq-after-positive-phase-3-results-in-adolescent-patients" target="_blank" rel="noreferrer noopener">BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients</a></li>
</ul>
Image: Shutterstock

Large Cap

Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?

ASPI

CENX

FEAM

MATV

MEOH

MERC

PACK

TECK

VALE

Shares of companies within the broader materials sector are trading lower as markets react to President Trump's announcement of sweeping tariffs.

Canada PM Carney Says: Call With Trump Helped Canada Avoid Reciprocal Tariffs

TD Securities analyst Craig Hutchison maintains Trilogy Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#TSX">TMQ</a>) with a Hold and raises the price target from C$2 to C$2.25.

TSX:TMQ

TD Securities Maintains Hold on Trilogy Metals, Raises Price Target to C$2.25

<a href="https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids" title="https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids">https://investor.gm.com/news-releases/news-release-details/gm-reports-strong-q1-china-growth-evs-and-hybrids</a>

General Motors And Its Joint Ventures Announces It Delivered More Than 442,000 Units In China In Q1 2025

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) just pulled back the curtain on its cloud ambitions at OCI Day, giving investors a close-up look at <a href="https://www.benzinga.com/topic/artificial-intelligence">its AI-powered</a> data center expansion.
While AI demand continues to surge, JPMorgan analyst Mark R. Murphy remains cautious, maintaining a Neutral stance on Oracle stock with a $135 price target, below its current trading level of $145.86.
<h1 class="wp-block-heading">AI Demand: Booming, But Is It Enough?</h1>
Oracle is doubling down on its AI infrastructure, expanding its customer-facing regions from 69 to 101 in the past year. But while the company insists demand is outpacing supply, Murphy notes that this messaging feels less urgent than before. 
Still, Oracle's investment in AI data centers suggests confidence in sustained demand, despite growing chatter about an "overbuild" or even an AI bubble.
Read Also: <a href="https://www.benzinga.com/news/25/04/44613084/amazon-makes-surprise-bid-for-tiktok-amid-us-ban-threat-report">Amazon&#8217;s Surprise Bid For TikTok As U.S. Ban Threat Looms</a>
<h1 class="wp-block-heading">Training Vs. Inferencing: Oracle Sees No Difference</h1>
One of the most debated topics in AI infrastructure is the difference between training (building models) and inferencing (running models). While Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) leans heavily on inferencing for steady revenue, Oracle argues that for major customers, both processes look the same. This implies a more persistent AI compute need than skeptics might believe, said Murphy.
<h1 class="wp-block-heading">Bubble Concerns? Oracle Hedging Its Bets</h1>
With Microsoft CEO Satya Nadella warning of an AI "overbuild" and Alibaba Group Holdings Ltd's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) chairman hinting at a potential bubble, Oracle's response was refreshingly pragmatic, Murphy noted.
Oracle Executive Vice President Clay Magouyrk dodged long-term predictions, instead emphasizing infrastructure flexibility — stating Oracle could repurpose its GPUs for general computing or storage if AI demand wanes. This adaptability could prove crucial if the AI hype cycle falters.
<h1 class="wp-block-heading">Oracle's Data Center Push: Big, But Not The Biggest</h1>
The event took place at Oracle's Novva facility in Utah, a massive operation but one dwarfed by neighboring Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) data centers.
Oracle also showcased plans for an even larger facility in Abilene, Texas, suggesting its AI cloud ambitions are just getting started.
Murphy sees Oracle's AI-driven cloud expansion as a long-term play, but acknowledges near-term challenges — particularly hefty capital expenditures cutting into free cash flow.
While Oracle's growth trajectory is promising, it still faces hurdles in keeping up with hyperscaler giants. For now, the AI gold rush continues — but not without risks.
ORCL Price Action: Oracle stock is down 5.41% at $137.97 Thursday morning at publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44601400/nvidia-rival-amd-completes-4-9b-acquisition-of-zt-systems-to-strengthen-ai-and-data-center-dominance">Nvidia Rival AMD Completes $4.9B Acquisition Of ZT Systems To Strengthen AI And Data Center Dominance</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

AMZN

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

MSFT

ORCL

Oracle's AI Bet: Overbuilt Or Future-Proof? Analyst Weighs In

Press Releases

Canaan Inc. Announces December 2024 Bitcoin Production and Mining Operation Updates and Provides FY2025 Financial Guidance

Canaan Inc. to Participate in the "Digital Assets 2025: To Bitcoin and Beyond," Virtual Conference Presented by Maxim Group LLC

Fintech

Canaan Inc. Announces January 2025 Bitcoin Production and Mining Operation Updates

Canaan Inc. Announces February 2025 Bitcoin Production, Mining Operation Updates, and Preliminary Fourth Quarter 2024 Financial Results

Canaan Inc. Enters into Securities Purchase Agreement for Series A-1 Preferred Shares Financing and Completes First Tranche Closing

Canaan Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 26, 2025

Contracts

Canaan Inc. Expands Self-Mining Footprint in North America

Canaan Inc. Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

Financing

Mawson Infrastructure Group Inc. Executes New Customer Agreement with Canaan Inc., Growing and Expanding Digital Colocation Business with Latest-Gen ASICs

Canaan Unveils Avalon Q at Mining Disrupt 2025: a Professional-Grade Quiet Bitcoin Mining Solution for Home Use

MIGI

Apple

AstroNova

CompoSecure

Corsair Gaming

Diebold Nixdorf Incorporated Common stock

Diebold Nixdorf

Dell Technologies Inc. Class C Common Stock

Dell Technologies

Foxx Development Holdings Inc. - Common Stock

Foxx Development Hldgs

Hewlett Packard Enterprise Company Common Stock

Hewlett Packard

Immersion

IonQ

Eastman Kodak

NetApp

One Stop Systems

CPI Card

Pure Storage

Quantum

Super Micro Computer, Inc. - Common Stock

Super Micro Computer

SanDisk

Sonim Technologies

Seagate Technology Holdings PLC - Ordinary Shares (Ireland)

Seagate Tech Hldgs

TransAct Technologies Incorporated - Common Stock

Transact Technologies

Turtle Beach

Western Digital Corporation - Common Stock

Western Digital

Xerox Holdings Corporation - Common Stock

Xerox Holdings

HC Wainwright & Co.

Rosenblatt

Compass Point

B. Riley Securities

Benchmark

비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)이 도널드 트럼프의 당선 이후 사상 최고가로 급등했으며, 이는 긍정적인 시장 심리의 파도로 비트코인 채굴 관련 주식들도 상승하는 결과를 가져왔다. 여러 비트코인 채굴 회사들이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41888686/bitcoin-blasts-through-87000-as-market-euphoria-regulatory-optimism-take-hold" target="_blank" rel="noopener">수요일 개장 전</a> 실적을 발표할 예정이므로 주목할 점을 살펴보겠다.
헛 8 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>)의 최근 <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41191549/hut-8-releases-bitcoin-mining-update-what-to-know">채굴 업데이트</a>에 따르면, 9월에 85 비트코인이 생산되었고 해시레이트는 19.5 엑사해시/초(EH/s)였다. 투자자들은 분기별 채굴 총량과 평균 해시레이트에 대한 업데이트, 그리고 3분기부터 매출을 발생시키기 시작한 자사의 GPUaaS(GPU-as-a-service) 자회사 하이라이즈 AI(Highrise AI, Inc)에 대한 업데이트를 주목할 것이다.
&#8211; 참고: EH/s는 1초에 백경개의 계산속도. 
헛 8 주식은 비트코인 가격이 사상 최고가에 도달하면서 월요일에 52주 최고가인 25.32달러를 기록했다. 애널리스트들은 이 회사가 주당 33센트의 손실과 3,846만 8,000달러의 분기 매출을 보고할 것으로 예상하고 있다.
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0%EC%9D%98-%EC%83%81%EC%9E%A5-%ED%8F%90%EC%A7%80-%EC%9C%84%ED%97%98%EC%9D%B4-17%EC%96%B5-%EB%8B%AC%EB%9F%AC-%EC%B1%84/" target="_blank" rel="noopener">슈퍼 마이크로 상장폐지 위험으로 17억 달러 채무 상환 위기</a>
비트팜즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>)의 10월 채굴 업데이트에 따르면, 이 회사의 채굴 작업에서 236 비트코인이 생성되었고 평균 운영 EH가 월 동안 3% 증가했다. 이 회사는 연말 효율성 목표인 21 w/TH를 3개월 앞당겨 달성했다고 보고했으나, 중간 목표인 12 EH/s는 일정이 지연되었다고 밝혔다.
투자자들은 비트팜즈의 효율성과 해시레이트 업데이트를 주목할 것이다. <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">벤징가 프로</a>의 추정에 따르면, 애널리스트들은 비트팜즈가 주당 10센트의 손실과 4,884만 2,000달러의 분기 매출을 보고할 것으로 예상한다.
캔터 피츠제럴드(Cantor Fitzgerald)의 애널리스트인 브렛 노블라흐(Brett Knoblauch)는 최근 하이브 디지털 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>)에 대한 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41603920/hive-pushes-hash-rate-higher-sharpens-focus-on-ai">커버리지를 시작</a>하며 비중확대 등급과 9달러의 목표 주가를 제시했다. 노블라흐는 하이브를 상위 10개 채굴업체 중 하나로 강조하며, 시장이 &#8220;다음 해시레이트 성장 전환점을 과소평가하고 있다&#8221;고 말했다.
하이브 디지털은 월요일에 카난 &#8211; ADR(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/can" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CAN" data-google-interstitial="false">CAN</a>)으로부터 각각 평균 185 테라해시/초(TH/s)의 컴퓨팅 파워를 제공하는 6,500개의 아발론(Avalon) A1566 채굴기를 <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41874534/canaan-secures-major-mining-deal-with-hive-shares-soar-on-equipment-order" target="_blank" rel="noopener" data-google-interstitial="false">받을 것</a>이라고 발표했다. 초기 500대의 배송은 이미 완료되어 즉시 설치될 예정이다.
투자자들은 하이브가 수요일 개장 전에 보고할 때 채굴 총량과 평균 해시레이트를 주목할 것이다. 애널리스트들은 이 회사가 주당 9센트의 손실과 2,569만 달러의 분기 매출을 보고할 것으로 예상하고 있다.
전문가 의견: H.C. 웨인라이트의 애널리스트인 마이크 콜로니즈(Mike Colonnese)는 트럼프의 당선 승리 이후 비트코인 채굴업체와 암호화폐 부문에 대한 업데이트를 발표했다. 이 애널리스트는 &#8220;암호화폐 산업에 대한 주요 규제 부담이 해소되면서 앞으로의 전망이 밝다&#8221;고 평가했다.
&#8220;미국의 비트코인 채굴 산업과 더 넓은 암호화폐 분야의 미래는 그 어느 때보다 밝다&#8221;고 콜로니즈가 썼다.

더 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">트럼프의 잠재적 &#8216;헬스 차르&#8217; 로버트 F. 케네디 주니어, 백신 주식에 충격: &#8216;먼저 쏘기 반응&#8217;</a></li>
</ul>
사진: Be Ba from Pixabay
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Canaan

뉴스

에 대한 최신 뉴스 Canaan (NASDAQ:CAN) 주식

화요일, 11월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌